n18
VIDEO |Tamil
   |
videos

Biocon sees larger licensing income from pharma

last updated on January 25, 2012 at 7:52 pm moneycontrol

Biocon, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.

Tags : #Kiran Mazumdar #Biocon

0 Like 0 Dislike
Content Missing | Report Abuse

Copyright Violation

Offensive or Abusive

Sexual or Pornography,

Hateful or Racism,

Violent or Repulsive

YOU MAY LIKE

03:09 26 May 2012 from Moneycontrol

Jet Air wants to boost income via ancillary activities

Moneycontrol Bureau  After posting a fifth straight quarterly loss in the Jan-March quarter, Jet Airways is trying hard to prune its operating costs and improve sales. This, the airline believes can be achieved by cutting down loss-making...

11:59 26 May 2012 from Moneycontrol

ITC Q4 total income up 17% at Rs 6955cr

By Gautam Broker, CNBC-TV18 Cigarettes to FMCG and hotels major ITC's fourth quarter net profit rose a better-than-expected 26% year-on-year to Rs 1,614 crore. While overall the company continues to be driven by cigarettes, quarterly earnings were...

11:19 25 May 2012 from FirstPost

HSBC sees "no big deals" as pay row fizzles

London: HSBC said it had no appetite to take advantage of turmoil in the euro zone and make big acquisitions there or anywhere else where rivals are selling major assets."We're good at running our own businesses, we're not so good at making...

N18 Msg

Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in. Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.